Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

BACKGROUND: Anti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastacky, Melissa L., Wang, Hong, Fortman, Dylan, Rahman, Zahra, Mascara, Gerard P., Brenner, Timothy, Najjar, Yana G., Luke, Jason J., Kirkwood, John M., Zarour, Hassane M., Davar, Diwakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662734/
https://www.ncbi.nlm.nih.gov/pubmed/34900695
http://dx.doi.org/10.3389/fonc.2021.749064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662734/
https://www.ncbi.nlm.nih.gov/pubmed/34900695
http://dx.doi.org/10.3389/fonc.2021.749064

Ejemplares similares